BioCentury | Nov 18, 2020
Emerging Company Profile

InterVenn: liquid biopsy diagnostics based on glycoproteins

InterVenn is tapping the glycoproteome for new markers for blood-based cancer diagnostics and using machine learning to accelerate the biomarker discovery process.  The company announced Monday that...
BioCentury | Jun 26, 2020
Distillery Therapeutics

Increasing PXR activity to treat acute kidney injury

DISEASE CATEGORY: Renal INDICATION: Renal damage Promoting the activity of the transcription factor PXR could treat acute kidney injury (AKI). PXR protein levels in renal tubular cells were lower in kidney biopsies from 20 AKI...
BioCentury | Jan 16, 2020
Company News

Jan. 15 Company Quick Takes: Japan Tobacco gets rights to Dermavant therapy; plus Clovis, BMS, Recordati, BeiGene, Insilico-Pfizer, Novartis

...endogenous Cushing syndrome in adults. Recordati acquired worldwide rights to the inhibitor of CYP11B1 and ALDOS...
...efficiency and scale of manufacturing oligonucleotide therapies. Targets: AHR- Aryl hydrocarbon receptor; ALDOS (CYP11B2) - Aldosterone synthase...
BioCentury | Dec 20, 2019
Product Development

Pharma spinouts: a snapshot of where and how pharmas spin out their assets

...CinCor launched in May with a $50M series A round to develop CIN-107, a first-in-class ALDOS...
...biotechs. Data used in the analysis are from BioCentury’s BCIQ database. Targets ALDOS (CYP11B2) - Aldosterone synthase...
BioCentury | May 15, 2019

Sofinnova Investments-led syndicate forms CV play CinCor with $50M, Roche castoff

...launch CinCor with a $50 million series A and exclusive, worldwide rights to the pharma's aldosterone synthase...
...CEO Jon Isaacsohn told BioCentury the company acquired CIN-107 because of its specificity as an ALDOS... 2015 and $10 million in a series B in 2017. Targets: ALDOS (CYP11B2) - Aldosterone synthase...
BioCentury | Mar 29, 2019
Targets & Mechanisms

AACR moves in a myeloid direction

Myeloid cells are showing up everywhere at this year’s AACR conference, suggesting the research community is rapidly expanding the ways it can harness the cell types to improve cancer immunotherapy responses. One of those ways...
BioCentury | Feb 22, 2019
Targets & Mechanisms

Expansion into TNBC

With an RNA-binding small molecule that sensitizes HER2-negative cancers to Herceptin, Matt Disney’s latest study adds to the growing arsenal of preclinical therapies against triple-negative breast cancer. The only problem is the molecule may run...
BioCentury | Feb 14, 2019
Translation in Brief

New Therapeutic Targets and Biomarkers: January 2019

New Therapeutic Targets and Biomarkers: January 2019 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during January. Therapeutic targets are defined as any protein, gene or other molecule...
BioCentury | Jan 3, 2019
Distillery Therapeutics


INDICATION: Renal damage Mouse studies suggest inhibiting AKR1A1 or PKM2 could help treat acute kidney injury (AKI). In a mouse model of AKI, systemic AKR1A1 knockout or renal-specific PKM2 knockout increased survival and decreased tubular...
BioCentury | Nov 30, 2018
Targets & Mechanisms

Adhesion targets emerge at ASH 2018

The next wave of targets in blood cancers and hematology will come from adhesion molecules, innate immune cells and regulators of gene expression, according to BioCentury’s analysis of emerging targets at ASH 2018. BioCentury’s analysis...
Items per page:
1 - 10 of 39